



From Clinical Trials to Clinical Implications: PARP Inhibitor Combinations in Advanced Prostate Cancer

REFERENCES

1. Schaeffer E, Srinivas S, Antonarakis ES, et al. NCCN Clinical Practice Guidelines in Oncology: Prostate cancer. Published 2021.
https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf. Accessed April 27, 2021.
2. Barata PC, Mendiratta P, Heald B, et al. Targeted next-generation sequencing in men with metastatic prostate cancer: a pilot study. *Target Oncol*. 2018;13(4):495-500.
3. Gong Y, Fan L, Fei X, et al. Targeted next-generation sequencing reveals heterogenous genomic features in viscerally-metastatic prostate cancer. *J Urol*. 2021:101097ju0000000000001731.
4. Jardim DL, Millis SZ, Ross JS, Woo MS, Ali SM, Kurzrock R. Landscape of cyclin pathway genomic alterations across 5,356 prostate cancers: Implications for targeted therapeutics. *Oncologist*. 2021;26(4):e715-e718.
5. Schweizer MT, Antonarakis ES. Prognostic and therapeutic implications of DNA repair gene mutations in advanced prostate cancer. *Clin Adv Hematol Oncol*. 2017;15(10):785-795.
6. Mateo J, Seed G, Bertan C, et al. Genomics of lethal prostate cancer at diagnosis and castration resistance. *J Clin Invest*. 2020;130(4):1743-1751.
7. Abida W, Campbell D, Patnaik A, et al. Non-BRCA DNA damage repair gene alterations and response to the PARP inhibitor rucaparib in metastatic castration-resistant prostate cancer: Analysis from the Phase II TRITON2 study. *Clin Cancer Res*. 2020;26(11):2487-2496.
8. Abida W, Armenia J, Gopalan A, et al. Prospective genomic profiling of prostate cancer across disease states reveals germline and somatic alterations that may affect clinical decision making. *JCO Precis Oncol*. 2017;2017.
9. Lincoln SE, Nussbaum RL, Kurian AW, et al. Yield and utility of germline testing following tumor sequencing in patients with cancer. *JAMA Netw Open*. 2020;3(10):e2019452.
10. Giri VN, Knudsen KE, Kelly WK, et al. Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019. *J Clin Oncol*. 2020;38(24):2798-2811.
11. Loeb S, Giri VN. Clinical implications of germline testing in newly diagnosed prostate cancer. *Eur Urol Oncol*. 2021;4(1):1-9.
12. Loeb S, Byrne N, Walter D, et al. Knowledge and practice regarding prostate cancer germline testing among urologists: Gaps to address for optimal implementation. *Cancer Treat Res Commun*. 2020;25:100212.
13. Greenberg S, Slager S, Neil BO, et al. What men want: Qualitative analysis of what men with prostate cancer (PCa) want to learn regarding genetic referral, counseling, and testing. *Prostate*. 2020;80(5):441-450.
14. de Bono J, Mateo J, Fizazi K, et al. Olaparib for metastatic castration-resistant prostate cancer. *N Engl J Med*. 2020;382(22):2091-2102.
15. Hussain M, Mateo J, Fizazi K, et al. Survival with olaparib in metastatic castration-resistant prostate cancer. *N Engl J Med*. 2020;383(24):2345-2357.
16. Marshall CH, Sokolova AO, McNatty AL, et al. Differential response to olaparib treatment among men with metastatic castration-resistant prostate cancer harboring BRCA1 or BRCA2 versus ATM mutations. *Eur Urol*. 2019;76(4):452-458.



From Clinical Trials to Clinical Implications: PARP Inhibitor Combinations in Advanced Prostate Cancer

17. Abida W, Patnaik A, Campbell D, et al. Rucaparib in men with metastatic castration-resistant prostate cancer harboring a BRCA1 or BRCA2 gene alteration. *J Clin Oncol*. 2020;38(32):3763-3772.
18. Matulonis UA, Monk BJ. PARP inhibitor and chemotherapy combination trials for the treatment of advanced malignancies: does a development pathway forward exist? *Ann Oncol*. 2017;28(3):443-447.
19. Asim M, Tarish F, Zecchini HI, et al. Synthetic lethality between androgen receptor signalling and the PARP pathway in prostate cancer. *Nat Commun*. 2017;8(1):374.
20. Li L, Karanika S, Yang G, et al. Enzalutamide-induced "BRCAness" and PARP inhibition are synthetically lethal for castration-resistant prostate cancer. *Sci Signal*. 2017;10(480).
21. Clarke N, Wiechno P, Alekseev B, et al. Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial. *Lancet Oncol*. 2018;19(7):975-986.